BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $BMY readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05946941-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261118
DTEND;VALUE=DATE:20261119
SUMMARY:POETYK SjS-1 readout (P3) · Bristol-Myers Squibb $BMY
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Deucravacitinib 
 in Adults With Active Sjögren's Syndrome\n\nPrimary completion date: 2026
 -11-18 (estimated)\nPhase 3 · Immuno · Sjögren's Syndrome\nEnrollment: 
 774 · Sites: 199\n\nPrimary completion = last participant's primary-endpo
 int data collected\; topline results usually follow weeks to months later.
  Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://d
 atacutoff.com/radar.html?nct=NCT05946941\nhttps://clinicaltrials.gov/study
 /NCT05946941
URL:https://datacutoff.com/radar.html?nct=NCT05946941
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06122779-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:AURORA-HFpEF readout (P2) · Bristol-Myers Squibb $BMY
DESCRIPTION:Study to Evaluate Safety\, Tolerability and Drug Levels of BMS-
 986435/MYK-224 in Participants With Heart Failure With Preserved Ejection 
 Fraction (HFpEF)\n\nPrimary completion date: 2026-12-14 (estimated)\nOrigi
 nally planned: 2025-01-22 (+22.7 months)\nPhase 2 · Cardio-Met · Heart F
 ailure\nEnrollment: 227 · Sites: 86\n\nPrimary completion = last particip
 ant's primary-endpoint data collected\; topline results usually follow wee
 ks to months later. Sponsor-reported\, often an estimate. Not investment a
 dvice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06122779\nhttps://clini
 caltrials.gov/study/NCT06122779
URL:https://datacutoff.com/radar.html?nct=NCT06122779
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268886-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:TargetTau-1 readout (P2) · Bristol-Myers Squibb $BMY
DESCRIPTION:Study to Evaluate the Efficacy\, Safety\, and Tolerability of a
 n Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Earl
 y Alzheimer's Disease\n\nPrimary completion date: 2026-12-17 (estimated)\n
 Originally planned: 2027-03-25 (-3.2 months)\nPhase 2 · Neuro · Alzheime
 r Disease\, Early Onset\nEnrollment: 310 · Sites: 176\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06268
 886\nhttps://clinicaltrials.gov/study/NCT06268886
URL:https://datacutoff.com/radar.html?nct=NCT06268886
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:SUCCESSOR-1 readout (P3) · Celgene $BMY
DESCRIPTION:A Study to Evaluate Mezigdomide\, Bortezomib and Dexamethasone 
 (MEZIVd) Versus Pomalidomide\, Bortezomib and Dexamethasone (PVd) in Parti
 cipants With Relapsed or Refractory Multiple…\n\nPrimary completion date
 : 2027-01-10 (estimated)\nOriginally planned: 2025-11-03 (+14.2 months)\nP
 hase 3 · Oncology · Relapsed or Refractory Multiple Myeloma\nEnrollment:
  810 · Sites: 266\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT05519085\nhttps://clinicaltrials.gov/stud
 y/NCT05519085
URL:https://datacutoff.com/radar.html?nct=NCT05519085
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:CheckMate-1533 readout (P2) · Bristol-Myers Squibb $BMY
DESCRIPTION:A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolum
 ab in Combination With Intravenous Ipilimumab and Chemotherapy in Particip
 ants With Previously Untreated Metastatic …\n\nPrimary completion date: 
 2027-02-05 (estimated)\nPhase 2 · Oncology · Non-Small Cell Lung Cancer\
 nEnrollment: 76 · Sites: 38\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT06946797\nhttps://clinicaltrial
 s.gov/study/NCT06946797
URL:https://datacutoff.com/radar.html?nct=NCT06946797
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140836-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Repotrectinib readout (P3) · Bristol-Myers Squibb $BMY
DESCRIPTION:A Study of Repotrectinib Versus Crizotinib in Participants With
  Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS
 1-positive Non-Small Cell Lung Cancer (NSCL…\n\nPrimary completion date:
  2027-02-16 (estimated)\nOriginally planned: 2029-02-26 (-24.3 months)\nPh
 ase 3 · Oncology · Carcinoma\, Non-Small-Cell Lung\nEnrollment: 190 · S
 ites: 120\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT06140836\nhttps://clinicaltrials.gov/study/NCT0614
 0836
URL:https://datacutoff.com/radar.html?nct=NCT06140836
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab readout (P3) · Bristol-Myers Squibb $BMY
DESCRIPTION:A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab 
 Alone in Participants With Advanced Kidney Cancer\n\nPrimary completion da
 te: 2027-03-11 (estimated)\nOriginally planned: 2022-12-29 (+50.4 months)\
 nPhase 3 · Oncology · Renal Cell Carcinoma\nEnrollment: 437 · Sites: 78
 \n\nPrimary completion = last participant's primary-endpoint data collecte
 d\; topline results usually follow weeks to months later. Sponsor-reported
 \, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT03873402\nhttps://clinicaltrials.gov/study/NCT03873402
URL:https://datacutoff.com/radar.html?nct=NCT03873402
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782490-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:MSS readout (P2) · Celgene $BMY
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety and Tolerability of B
 MS-986368 in Participants With Multiple Sclerosis Spasticity\n\nPrimary co
 mpletion date: 2027-05-26 (estimated)\nOriginally planned: 2026-08-24 (+9.
 0 months)\nPhase 2 · Neuro · Multiple Sclerosis Spasticity\nEnrollment: 
 200 · Sites: 61\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://da
 tacutoff.com/radar.html?nct=NCT06782490\nhttps://clinicaltrials.gov/study/
 NCT06782490
URL:https://datacutoff.com/radar.html?nct=NCT06782490
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140913-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Xanomeline/Trospium Chloride readout (P3) · Bristol-Myers Squibb $
 BMY
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT
  for the Treatment of Mania\, With or Without Mixed Features\, in Particip
 ants With Bipolar-I Disorder Taking Lithium\,…\n\nPrimary completion dat
 e: 2027-06-28 (estimated)\nPhase 3 · Neuro · Mania\, Bipolar Disorder\nE
 nrollment: 424 · Sites: 109\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07140913\nhttps://clinicaltrial
 s.gov/study/NCT07140913
URL:https://datacutoff.com/radar.html?nct=NCT07140913
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05664737-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Luspatercept readout (P2) · Bristol-Myers Squibb $BMY
DESCRIPTION:A Study to Determine the Efficacy and Safety of Luspatercept in
  Adult Participants and to Evaluate the Safety and Pharmacokinetics in and
  Adolescent Participants With Alpha (α)-Th…\n\nPrimary completion date:
  2027-07-16 (estimated)\nOriginally planned: 2025-11-05 (+20.3 months)\nPh
 ase 2 · GI·Renal·Heme · Anemia\nEnrollment: 189 · Sites: 31\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nc
 t=NCT05664737\nhttps://clinicaltrials.gov/study/NCT05664737
URL:https://datacutoff.com/radar.html?nct=NCT05664737
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356129-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:GOLSEEK-1 readout (P3) · Celgene $BMY
DESCRIPTION:Study to Compare the Effectiveness and Safety of Golcadomide Pl
 us R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated
  High-risk Large B-cell Lymphoma\n\nPrimary completion date: 2027-08-09 (e
 stimated)\nOriginally planned: 2028-08-14 (-12.2 months)\nPhase 3 · Oncol
 ogy · Large B-cell Lymphoma\nEnrollment: 850 · Sites: 325\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 06356129\nhttps://clinicaltrials.gov/study/NCT06356129
URL:https://datacutoff.com/radar.html?nct=NCT06356129
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:BMS-986489 (Atigotatug+Nivolumab) readout (P3) · Bristol-Myers Squ
 ibb $BMY
DESCRIPTION:A Study to Compare the Efficacy and Safety of BMS-986489 (Atigo
 tatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin P
 lus Etoposide to That of Atezolizumab With…\n\nPrimary completion date: 
 2027-08-17 (estimated)\nOriginally planned: 2028-04-06 (-7.7 months)\nPhas
 e 3 · Oncology · Extensive-Stage Small Cell Lung Cancer\nEnrollment: 530
  · Sites: 183\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://data
 cutoff.com/radar.html?nct=NCT06646276\nhttps://clinicaltrials.gov/study/NC
 T06646276
URL:https://datacutoff.com/radar.html?nct=NCT06646276
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764485-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270912
DTEND;VALUE=DATE:20270913
SUMMARY:rechARge readout (P3) · Celgene $BMY
DESCRIPTION:A Study to Compare the Efficacy and Safety of BMS-986365 Versus
  the Investigator's Choice of Therapy in Participants With Metastatic Cast
 ration-resistant Prostate Cancer\n\nPrimary completion date: 2027-09-12 (e
 stimated)\nPhase 3 · Oncology · Metastatic Castration-resistant Prostate
  Cancer\nEnrollment: 960 · Sites: 227\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06764485\nhttps://cli
 nicaltrials.gov/study/NCT06764485
URL:https://datacutoff.com/radar.html?nct=NCT06764485
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:EXCALIBER-RRMM readout (P3) · Celgene $BMY
DESCRIPTION:Open-label Study Comparing Iberdomide\, Daratumumab and Dexamet
 hasone (IberDd) Versus Daratumumab\, Bortezomib\, and Dexamethasone (DVd) 
 in Participants With Relapsed or Refractory M…\n\nPrimary completion dat
 e: 2027-11-16 (estimated)\nOriginally planned: 2024-05-17 (+42.0 months)\n
 Phase 3 · Oncology · Multiple Myeloma\nEnrollment: 939 · Sites: 259\n\n
 Primary completion = last participant's primary-endpoint data collected\; 
 topline results usually follow weeks to months later. Sponsor-reported\, o
 ften an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.h
 tml?nct=NCT04975997\nhttps://clinicaltrials.gov/study/NCT04975997
URL:https://datacutoff.com/radar.html?nct=NCT04975997
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
